Key result
Melatonin treatment (preventive or curative) reduced right ventricular hypertrophy, improved right ventricular function, and reduced cardiac fibrosis in a rat model of pulmonary hypertension.
Why the study?
Does melatonin prevent or treat pulmonary hypertension and right ventricular dysfunction in a monocrotaline-induced rat model?
Does melatonin prevent or treat pulmonary hypertension and right ventricular dysfunction in a monocrotaline-induced rat model?
In a rat model of monocrotaline-induced pulmonary hypertension, melatonin provided both preventive and curative benefits by reducing right ventricular hypertrophy, fibrosis, and oxidative stress.
Answers are grounded in this paper and cite their sources.
Melatonin benefits in rat PH model warrant human trials; leaves open translation to clinical right ventricular outcomes.
Pulmonary hypertension (PH) is characterized by elevated pulmonary arterial pressure, which leads to right ventricular (RV) hypertrophy and failure. The pathophysiological mechanisms of PH remain unclear but oxidative stress is believed to contribute to RV dysfunction. Melatonin is a powerful antioxidant and is cardioprotective against ischemia-reperfusion injury and hypertension. Therefore, we hypothesized that a chronic treatment with melatonin, given as a curative or preventive therapy, may confer cardiovascular benefits in PH. PH was induced in Long Evans rats (n ≥ 6 per group), with a single subcutaneous injection of monocrotaline (MCT, 80 mg/kg). Melatonin was given daily in the drinking water, with the treatment starting either on the day of the injection of MCT (dose testing: melatonin 75 ng/L and 6 mg/kg), 14 days after the injection of MCT (curative treatment: 6 mg/kg), or 5 days before the injection (preventive treatment: 6 mg/kg). The development of PH was assessed by measuring RV hypertrophy, RV function, cardiac interstitial fibrosis, and plasma oxidative stress. Compared with controls, MCT-treated rats displayed RV hypertrophy and dysfunction, increased interstitial fibrosis, and elevated plasma oxidative stress. A chronic melatonin treatment (75 ng/L or 6 mg/kg) reduced RV hypertrophy, improved RV function and reduced plasma oxidative stress. Curative and preventive treatment improved RV functional and plasma oxidative stress parameters and reduced cardiac interstitial fibrosis. Our data demonstrate that melatonin confers cardioprotection in this model of PH. As melatonin is an inexpensive and safe drug, we propose that clinical investigation of the effects of melatonin on RV function in patients with PH should be considered.
No takes yet. Share an insight, caveat, or question.
Maarman et al. (2015) studied Pulmonary hypertension. Melatonin vs. Control (MCT-treated rats) was evaluated on Right ventricular hypertrophy, right ventricular function, cardiac interstitial fibrosis, and plasma oxidative stress. Melatonin treatment (preventive or curative) reduced right ventricular hypertrophy, improved right ventricular function, and reduced cardiac fibrosis in a rat model of pulmonary hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: